UTHR UNITED THERAPEUTICS Corp Insider Trading

Rothblatt sells 9,500 shares at $530.91 avg for $5.0M under pre-arranged 10b5-1 plan; retains 324.4K shares post-transaction

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 10 separate sales totaling 9,500 shares for $5,043,688.79 on 2026-07-16 under a pre-arranged 10b5-1 trading plan adopted 2025-11-07. The blended average price was $530.91, slightly below the current price of $535.67, representing a -2.8% reduction in her non-derivative holdings (from 333.9K to 324.4K shares). This is part of a scheduled divestment program, not a discretionary trade driven by market conditions. Her derivative holdings include 331,910 shares in stock options, meaning her total economic position extends well beyond the reported non-derivative stake.

Rothblatt sells 9,500 UTHR shares for $5.0M via scheduled 10b5-1 plan on 2026-07-15

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 21 separate sales totaling 9,500 shares for $5,038,339.77 on 2026-07-15 at blended average price of $530.35. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning it was scheduled rather than discretionary. Post-transaction, Rothblatt retains 324,443 non-derivative shares (a -2.8% reduction in non-derivative holdings), with an additional 341,410 shares held through derivative securities, indicating her overall position remains substantial. The stock is currently trading at $531.79, down 12.7% from its 52-week high of $609.35 and down 3.2% over the past 30 days, reflecting sector or company-specific headwinds; however, timing characterization is not applicable to scheduled 10b5-1 executions.

EVP & General Counsel Paul A Mahon sells 8,300 shares at blended avg $533.69 via scheduled 10b5-1 plan.

Paul A Mahon, EVP & General Counsel at United Therapeutics, executed 8 separate sales totaling 8,300 shares for $4,429,637.90 on 2026-07-16, reducing his non-derivative holdings from 53,472 shares to 45,172 shares (a -15.5% reduction). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled and not discretionary. Mahon retains 80,740 shares in stock options (derivative holdings), so his overall economic position at the company remains substantial. The sales occurred as UTHR stock is trading at $531.79, down 12.7% from its 52-week high of $609.35 and down 3.2% over the past 30 days, though the company exhibits solid fundamentals with $781.5M in latest-quarter revenue, $274.9M net income, and a P/E of 17.53. The scheduled nature of this transaction under a 10b5-1 plan precludes characterization based on timing considerations.

Rothblatt (CEO) sells 9,500 shares for $5.0M on scheduled 10b5-1 plan; retains 40.5K shares plus 1,718 stock options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 9 separate sales totaling 9,500 shares for $5,004,908.73 on 2026-07-14 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, with transaction prices ranging from $524.15 to $531.08 and a blended average of $526.83. This follows five prior same-ticker sales on 2026-07-13 under the same plan, indicating an ongoing scheduled liquidation of a portion of her holdings. Post-transaction, she retains 40.5K shares plus 1,718 stock options (derivative holdings), representing a -19.0% reduction in non-derivative holdings from 50.0K shares. The company's fundamentals show strong performance with $781.5M latest-quarter revenue, $274.9M net income, and a P/E of 17.53, while the stock trades -12.7% from its 52-week high of $609.35 and -3.2% from its 30-day average. The scheduled nature of these sales removes discretionary timing signals, but the cumulative volume across consecutive days and the CEO's continued material holdings position warrant monitoring.

CEO Rothblatt sells 9,500 shares for $5.1M via 9 separate transactions; 10b5-1 plan execution, holds 40.5K non-derivative shares post-sale.

Martine A Rothblatt, Chairperson & CEO, executed 9 separate sales totaling 9,500 shares for $5,091,949.44 on 2026-07-13 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07. This is a scheduled transaction, not a discretionary choice. Her non-derivative holdings decreased from 50,013 shares to 40,513 shares (a 19.0% reduction of pre-transaction holdings), while she retains 11,218 shares in stock option form. The stock has declined 13.6% from its 52-week high of $609.35 and is down 3.5% over 30 days and 8.8% over 90 days from the current price of $526.66, though the blended sale price of $535.99 suggests execution across a tight intraday window. With fundamentals showing revenue of $781,500,000.00 and net income of $274,900,000.00 in the latest quarter, plus annual revenue growth of 10.6%, the underlying business remains profitable, making this a routine vest-and-sell execution under a pre-existing plan rather than a signal of changed conviction.

CEO Martine A Rothblatt sold 9,500 shares at blended avg $544.60 on 2026-07-10 via 10b5-1 plan; retains 40,513 shares plus 20,718 stock options.

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 10 separate sales totaling 9,500 shares for $5,173,659.73 on 2026-07-10 at prices ranging from $540.37 to $553.47 (blended average $544.60). This trade was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, making it scheduled rather than discretionary. Post-transaction, Rothblatt retains 40,513 non-derivative shares and 20,718 stock options, representing a -19.0% reduction in her non-derivative holdings from the 50,013 shares held before the sale. The current stock price of $535.57 sits -12.1% below the 52-week high of $609.35 and has declined -7.4% over the past 90 days, providing context for when these sales occurred relative to recent price movement. As a scheduled 10b5-1 execution rather than a discretionary open-market decision, this sale reflects systematic portfolio management aligned with a pre-existing plan rather than a tactical response to current market conditions.

CEO Rothblatt executes 8 scheduled sales totaling 9,500 shares ($5.2M) under 10b5-1 plan

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 8 separate sales on 2026-07-09 totaling 9,500 shares for $5,235,756.08, reducing her non-derivative holdings from 50,013 to 40,513 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning the sales follow a scheduled program rather than a discretionary decision. The blended average sale price of $551.13 compares closely to the current price of $552.48, and the stock has declined 9.3% from its 52-week high of $609.35. Notably, Rothblatt retains 30,218 shares in stock options (derivative holdings), so her overall position remains material despite this 19.0% reduction in non-derivative holdings.

CEO Martine Rothblatt sold 9,500 shares for $5,255,111.49 on 2026-07-08 via pre-arranged 10b5-1 plan.

Martine A Rothblatt, Chairperson & CEO, executed 12 separate sales totaling 9,500 shares for $5,255,111.49 on 2026-07-08 at blended average price $553.17. This represents a -19.0% reduction in non-derivative holdings (from 50,013 to 40,513 shares), executed through a pre-arranged 10b5-1 trading plan adopted 2025-11-07 and therefore scheduled rather than discretionary. The insider retains 39,718 shares in stock options, preserving material equity exposure. The current stock price of $554.34 sits -9.0% from the 52-week high of $609.35, and the company reported $781,500,000.00 in latest-quarter revenue with net income of $274,900,000.00 and annual revenue growth of +10.6%.

Rothblatt (UTHR CEO) executes 10 separate sales totaling 9,500 shares for $5,309,295.75 via scheduled 10b5-1 plan

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 10 separate sales on 2026-07-07 totaling 9,500 shares for $5,309,295.75 at prices ranging from $553.12 to $563.24, reducing non-derivative holdings from 50,013 shares to 40,513 shares (-19.0%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted 2025-11-07, meaning it was scheduled rather than discretionary. Rothblatt retains 49,218 shares in stock options (Table II derivative holdings), preserving significant ongoing equity exposure. The blended average sale price of $558.87 is above the current market price of $554.34, though the stock trades near recent highs (only -9.0% from the 52-week peak of $609.35), providing context on the liquidation prices achieved.

UTHR CEO Rothblatt sells 9,500 shares for $5.2M via 10b5-1 plan; holds 40.5K shares post-sale plus 58,718 stock options

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 8 separate sales totaling 9,500 shares for $5,215,133.37 on 2026-07-06 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07. This is a scheduled, non-discretionary transaction; her non-derivative holdings decline from 50,013 shares to 40,513 shares, while she retains 58,718 stock options. The sale occurred near the stock's 52-week range context ($272.12–$609.35, current price $547.25), and follows a pattern of recent activity at this ticker with 5 prior sells on 2026-06-29. Given the executive's substantial remaining non-derivative position and material derivative holdings, this represents a partial liquidation of a specific vested batch under contractual plan terms, not a signal of conviction change.